Headquartered in Israel, the birthplace of modern medical cannabis research, the Research Division leverages the Company’s extensive network comprising some of Israel’s leading researchers, scientists, universities and hospitals, as well as cannabis breeders and extractors, to study and test the effectiveness of different combinations of cannabinoids in the treatment of disease and chronic conditions.
One World Cannabis is focused on discovering, developing and commercializing cannabis-based novel therapeutics products and treatments specifically designed for several medical conditions, starting with multiple myeloma, psoriasis, fibromyalgia, migraine and PTSD (post-traumatic stress disorder).
To date, One World Cannabis has signed research collaboration agreements with a big Academic Medical Center in Israel. Within the framework of these agreements, the company will initiate pre-clinical and clinical studies to explore the effect of several combinations of cannabidiol (CBD) and tetrahydrocannabinol (THC) on multiple myeloma (a cancer of plasma cells), psoriasis and fibromyalgia.
One World Cannabis will continue to collaborate with other industry partners, as well as leading academic medical centers, in order to develop, clinically research, produce, and commercialized novel cannabinoid-based therapies targeting a variety of different indications and effectively help patients in need.
Upon the successful completion of clinical trials and the development of appropriate dosing forms and delivery systems for pharmaceutical-grade cannabis-based preparations, One World cannabis will determine which markets and distribution channels are most suitable for any given product or formulation. In all cases, the Company will retain the intellectual property rights to proprietary discoveries made in conjunction with its initiatives and seek to secure patent protections.
One World Cannabis filed eight provisional patent applications and PCTs, all related to its line of activity (pharmaceutical formulations; drug delivery; therapeutic uses of cannabinoids and other cannabis compounds), as well as know-how and trade secrets.
The Company plans to continue to seek patent protection in the United States and other countries for our proprietary technologies.
For further information, read our Press Releases